Plain English Summary
Background and study aims
Patients with chronic obstructive pulmonary disease (COPD), which is a combination of chronic bronchitis and emphysema, are limited in their daily activates because of breathlessness. However, there is increasing evidence that their muscle function is also reduced which can further limit them, so we are investigating a dietary supplement that may be helpful. Muscle metabolism and blood flow are influenced by a substance called nitric oxide (NO). Levels of this can be influenced by dietary nitrate consumption (found in leafy green vegetables and especially in beetroot). There is evidence that beetroot juice can improve exercise performance in athletes and we want to test whether it will improve exercise performance in people with COPD.
Who can participate?
We will study 25 people with COPD.
What does the study involve?
After baseline assessments of lung function and exercise capacity, patients will perform two maximum exercise tests. One after consuming 70mls of beetroot juice and one after consuming 70mls of beetroot juice treated to remove the nitrate (placebo). They taste identical and patients and researchers will not know which they have consumed. The primary endpoint (or (measure of success) of the study is the time that patients can cycle on a bike in our laboratory at a workload that is 70% of the maximum they can reach. Oxygen consumption and muscle metabolism (using a technique called near infrared spectroscopy) will be assessed. We will take blood samples to monitor the effect of the juice/placebo on nitrate levels.
What are the possible benefits and risks of participating?
The procedures are all routine so no risks are anticipated: If positive, this initial study would lead to a larger research study to evaluate the use of this supplement more widely in patients with COPD.
Where is the study run from?
The study is being performed at The Royal Brompton Hospital and is supported by Imperial College (UK).
When is the study starting and how long is it expected to run for?
It is expected to run from the beginning of May 2013 until the end of 2014.
Who is funding the study?
It is funded from Royal Brompton Hospital Departmental funds (UK).
Who is the main contact?
Dr Nicholas Hopkinson
EDEN-EPIC: Effect of dietary nitrate supplementation on exercise performance in COPD - a randomised double-blind cross-over placebo controlled trial
The purpose of this study is to investigate the effects of an acute administration of beetroot (BR) juice versus placebo beverage ingestion on plasma NO2- levels, blood pressure, exercise tolerance and fractional oxygen extraction.
13/LO/0372 - London Bromley Research Ethics Committee
Randomised double-blind cross-over placebo-controlled trial
Primary study design
Secondary study design
Randomised cross over trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Chronic obstructive pulmonary disease (COPD)
Current interventions as of 03/06/2015:
140 ml concentrated beetroot juice or matched nitrate-depleted placebo.
70 ml concentrated beetroot juice or matched nitrate-depleted placebo.
Dietary nitrate supplementation (beetroot juice)
Primary outcome measures
Time to exhaustion in a fixed workload cycle ergometer test at 70% VO2max
Secondary outcome measures
1. Area under VO2 curve to isotime (VO2) during endurance cycle ergometry
2. Fractional oxygen extraction of quadriceps muscle as assessed by NIRS
Overall trial start date
Overall trial end date
Participant inclusion criteria
Adult patients with a clinical and spirometric diagnosis of COPD, GOLD stage II-IV.
Target number of participants
Participant exclusion criteria
Clinically unstable patients (within one month of exacerbation), significant comorbidity limiting exercise tolerance, significant renal impairment (estimated glomerular filtration rate (eGFR) <50 ml.min-1), hypotension (systolic blood pressure <100 mmHg), pregnancy, use of nitrate based medication, other reason for benefit from nitrate supplementation (ischaemic heart disease, peripheral arterial disease), use of long-term oxygen therapy.
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Royal Brompton Hospital
Imperial College London and Imperial College Healthcare NHS Trust (UK)
c/o Lucy Parker
5th floor Lab Block
Charing Cross Hospital
Fulham Palace Road
Royal Brompton Hospital (UK)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting